A critical study in the battle to reduce the severity of Alzheimer’s disease, the most common form of dementia, is coming to New Jersey.
The Rutgers Robert Wood Johnson Medical School has been chosen as one of about 40 sites across the U.S. to see how well benfotiamine — a synthetic form of vitamin B1 — can slow cognitive decline in people with mild dementia and early Alzheimer’s.
Recognition: Scott Fallon, NorthJersey.com